In silico investigation of ketamine and methylphenidate drug-drug conjugate for MDD and ADHD treatment using MD simulations and MMGBSA

Major depressive disorder (MDD) and Attention-deficit hyperactivity disorder (ADHD) are pervasive psychiatric disorders characterized by impaired memory, sustained attention/motivation, and depression. FDA-approved Ketamine is an antidepressant drug but it affects cognitive abilities. Methylphenidate is the drug used for the treatment of ADHD. Chronic treatment overcomes attention and mental problems but causes depression. In the current study, we have made ketamine-methylphenidate conjugate to…

via https://pubmed.ncbi.nlm.nih.gov/40628750/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1L37KAMf2b_g4WEK3LmdFuKZu9pO3cN7u4ZmO9PPCPeBLMIw1q&fc=None&ff=20250721010906&v=2.18.0.post9+e462414